A Phase 2 interventional study of Ninerafaxstat 200mg MR and Placebo in Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Imbria Pharmaceuticals, Inc.. Recruiting at 76 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Imbria Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Cardiomyopathy, Hypertrophic with a site in United States — 23 open to participants now, 37 under way, 6 of them phase 3. Cardiomyopathy, Hypertrophic · United States.
Among the 125 studies in Cardiomyopathy, Hypertrophic with a site in United States, this one is the 17th largest by planned enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2025, is one of 21 in phase 2, reaches primary completion later than 11 of the 36 other live ones, and was the 114th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →23 of the 125 studies in Cardiomyopathy, Hypertrophic with a site in United States are open now. Recruiting first, the newest first:
Haya Therapeutics, Inc. · Sites in United States
Ages 18–70 · Healthy volunteers
Braveheart Bio, Inc. · Sites in United States
Ages 18–85
Christopher Kramer · Sites in United States, United Kingdom
Ages 18–65
Lexeo Therapeutics · Sites in United States
Ages 6+
Oregon Health and Science University · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 27 · Phase 3 14 · Phase 4 5
First in 1987; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is above the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 50 across the 65 interventional studies, 150 across the 58 observational. Of the 80 that completed or were terminated, 25 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 125 have an industry lead sponsor. The 10 most frequent:
Imbria Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Imbria Pharmaceuticals, Inc. has 2 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
10 of the studies in Cardiomyopathy, Hypertrophic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06481891Phase 3Lexicon PharmaceuticalsA Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | 2027-01 |
| NCT07023614Imbria Pharmaceuticals, Inc.A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy | 2026-12 |
| NCT07600177Oregon Health and Science UniversityMavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy | 2026-12-31 |
| NCT06551129Bristol-Myers SquibbReal-world Patient Reported Outcomes Among Patients Treated With Camzyos | 2026-12-31 |
| NCT07867288Haya Therapeutics, Inc.Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001 | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 125 studies in Cardiomyopathy, Hypertrophic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM
Select Inclusion Criteria:
Select Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ninerafaxstat 200mg MR
Drug: Placebo
Ninerafaxstat 200mg Modified Release tablet administered BID
Matching placebo tablet administered BID
Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
The Clinical Summary Score is a merging of symptom frequency and symptom burden domains into a total symptom score combined with the physical limitation domain. Scoring ranges from 0 to 100, with higher scores indicating better health status.
Time frame: Baseline to Week 12
Change in ventilatory efficiency (VE/VCO2 slope) during cardiopulmonary exercise testing (CPET)
Time frame: Baseline to Week 12
Change in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS)
The Total Symptom Score is a merging of symptom frequency and symptom burden domains. Scoring ranges from 0 to 100, with higher scores indicating better health status.
Time frame: Baseline to Week 12
Change in the Kansas City Cardiomyopathy Questionnaire Physical Limitations Score (KCCQ-PLS)
The Physical Limitations Score is a single-domain score. Scoring ranges from 0 to 100, with higher scores indicating better health status.
Time frame: Baseline to Week 12
Change in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS)
The Overall Summary Score is a merging of symptom, physical limitations, social limitations, and quality of life domains. Scoring ranges from 0 to 100, with higher scores indicating better health status.
Time frame: Baseline to Week 12
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.
Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ninerafaxstat
Cardiomyopathy, Hypertrophic →
Imbria Pharmaceuticals, Inc.